Surgical benchmarks, mid-term oncological outcomes, and impact of surgical team composition on simultaneous enbloc robot-assisted radical cystectomy and nephroureterectomy.
Aged
Aged, 80 and over
Benchmarking
Carcinoma, Transitional Cell
/ surgery
Cystectomy
/ methods
Female
Humans
Kidney Neoplasms
/ surgery
Male
Nephroureterectomy
/ methods
Patient Care Team
Prospective Studies
Robotic Surgical Procedures
Time Factors
Treatment Outcome
Ureteral Neoplasms
/ surgery
Urinary Bladder Neoplasms
/ surgery
Minimally invasive surgery
Radical cystectomy
Radical nephroureterectomy
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
28 Apr 2021
28 Apr 2021
Historique:
received:
03
12
2020
accepted:
15
04
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
18
9
2021
Statut:
epublish
Résumé
Simultaneous urothelial cancer manifestation in the lower and upper urinary tract affects approximately 2% of patients. Data on the surgical benchmarks and mid-term oncological outcomes of enbloc robot-assisted radical cystectomy and nephro-ureterectomy are scarce. After written informed consent was obtained, we prospectively enrolled consecutive patients undergoing enbloc radical cystectomy and nephro-ureterectomy with robotic assistance from the DaVinci Si-HD® system in a prospective institutional database and collected surgical benchmarks and oncological outcomes. Furthermore, as one console surgeon conducted all the procedures, whereas the team providing bedside assistance was composed ad hoc, we assessed the impact of this approach on the operative duration. Nineteen patients (9 women), with a mean age of 73 (SD: 7.5) years, underwent simultaneous enbloc robot-assisted radical cystectomy and nephro-ureterectomy. There were no cases of conversion to open surgery. In the postoperative period, we registered 2 Clavien-Dindo class 2 complications (transfusions) and 1 Clavien-Dindo class 3b complication (port hernia). After a median follow-up of 23 months, there were 3 cases of mortality and 1 case of metachronous urothelial cancer (contralateral kidney).The total operative duration did not decrease with increasing experience (r = 0.174, p = 0.534). In contrast, there was a significant, inverse, strong correlation between the console time relative to the total operative duration and the number of conducted procedures after adjusting for the degree of adhesions and the type of urinary diversion(r = -0.593, p = 0.02). These data suggest that en bloc simultaneous robot-assisted radical cystectomy and nephro-ureterectomy can be safely conducted with satisfactory mid-term oncological outcomes. With increasing experience, improved performance was detectable for the console surgeon but not in terms of the total operative duration. Simulation training of all team members for highly complex procedures might be a suitable approach for improving team performance. Not applicable. Video Abstract.
Sections du résumé
BACKGROUND
BACKGROUND
Simultaneous urothelial cancer manifestation in the lower and upper urinary tract affects approximately 2% of patients. Data on the surgical benchmarks and mid-term oncological outcomes of enbloc robot-assisted radical cystectomy and nephro-ureterectomy are scarce.
METHODS
METHODS
After written informed consent was obtained, we prospectively enrolled consecutive patients undergoing enbloc radical cystectomy and nephro-ureterectomy with robotic assistance from the DaVinci Si-HD® system in a prospective institutional database and collected surgical benchmarks and oncological outcomes. Furthermore, as one console surgeon conducted all the procedures, whereas the team providing bedside assistance was composed ad hoc, we assessed the impact of this approach on the operative duration.
RESULTS
RESULTS
Nineteen patients (9 women), with a mean age of 73 (SD: 7.5) years, underwent simultaneous enbloc robot-assisted radical cystectomy and nephro-ureterectomy. There were no cases of conversion to open surgery. In the postoperative period, we registered 2 Clavien-Dindo class 2 complications (transfusions) and 1 Clavien-Dindo class 3b complication (port hernia). After a median follow-up of 23 months, there were 3 cases of mortality and 1 case of metachronous urothelial cancer (contralateral kidney).The total operative duration did not decrease with increasing experience (r = 0.174, p = 0.534). In contrast, there was a significant, inverse, strong correlation between the console time relative to the total operative duration and the number of conducted procedures after adjusting for the degree of adhesions and the type of urinary diversion(r = -0.593, p = 0.02).
CONCLUSIONS
CONCLUSIONS
These data suggest that en bloc simultaneous robot-assisted radical cystectomy and nephro-ureterectomy can be safely conducted with satisfactory mid-term oncological outcomes. With increasing experience, improved performance was detectable for the console surgeon but not in terms of the total operative duration. Simulation training of all team members for highly complex procedures might be a suitable approach for improving team performance.
TRIAL REGISTRATION
BACKGROUND
Not applicable. Video Abstract.
Identifiants
pubmed: 33910552
doi: 10.1186/s12894-021-00839-y
pii: 10.1186/s12894-021-00839-y
pmc: PMC8082848
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
73Références
J Laparoendosc Adv Surg Tech A. 2018 Oct;28(10):1157-1162
pubmed: 29708828
J Minim Invasive Gynecol. 2015 Sep-Oct;22(6):1049-58
pubmed: 26070725
Cancer Epidemiol. 2013 Jun;37(3):219-25
pubmed: 23485480
J Endourol. 2017 Jan;31(1):38-42
pubmed: 27806631
Int Braz J Urol. 2008 Jul-Aug;34(4):413-21; discussion 421
pubmed: 18778492
Eur Urol. 2014 Apr;65(4):778-92
pubmed: 24373477
J Robot Surg. 2017 Sep;11(3):305-309
pubmed: 27830431
J Urol. 2005 Sep;174(3):859-61; discussion 861
pubmed: 16093970
Eur Urol Focus. 2021 Mar;7(2):352-358
pubmed: 32061537
Curr Urol Rep. 2017 Sep 23;18(11):89
pubmed: 28942572
J Robot Surg. 2016 Jun;10(2):129-34
pubmed: 27039192
Eur Urol. 2004 Aug;46(2):147-54
pubmed: 15245806
BMC Cancer. 2020 Nov 25;20(1):1148
pubmed: 33238972
BJU Int. 2008 Jun;101(11):1368-74
pubmed: 18241252
Curr Urol. 2012 Sep;6(2):76-81
pubmed: 24917718
Surg Endosc. 2011 Jul;25(7):2288-95
pubmed: 21298533
Br J Surg. 2018 Jul;105(8):1061-1069
pubmed: 29558567
J Endourol. 2011 Jun;25(6):979-84
pubmed: 21476927
Curr Urol Rep. 2017 Aug;18(8):58
pubmed: 28647793
BMJ Qual Saf. 2012 Jan;21(1):3-12
pubmed: 22003174
Anesth Analg. 2009 Oct;109(4):1232-45
pubmed: 19762753
Anesthesiol Clin. 2015 Dec;33(4):697-711
pubmed: 26610624
JAMA Surg. 2018 Aug 1;153(8):770-771
pubmed: 29926095
Eur Urol. 2016 Jun;69(6):1065-80
pubmed: 26433570
BJU Int. 2016 Mar;117(3):515-30
pubmed: 26352342
Anesthesiology. 2010 Jan;112(1):41-9
pubmed: 19952726
J Urol. 2002 May;167(5):2125-6
pubmed: 11956456
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Aktuelle Urol. 2012 Jul;43(4):255-61
pubmed: 22869496
J Urol. 2012 Dec;188(6):2046-54
pubmed: 23083867
BJU Int. 2018 Dec;122(6):1075-1081
pubmed: 29733492
J Robot Surg. 2016 Dec;10(4):315-322
pubmed: 27153839
Surg Endosc. 2016 Jun;30(6):2169-78
pubmed: 26304107
JSLS. 2018 Jan-Mar;22(1):
pubmed: 29618918